Search

Displaying results 3211 - 3220 of 10000 in total
  1. Drug

    Alectinib

    go.drugbank.com/drugs/DB11363
    ApprovedInvestigational

    Approved under accelerated approval in 2015, alectinib is indicated for use in patients who have progressed on or were not tolerant of crizotinib, which is associated with the development of resistance … It is specifically used in the treatment of non-small cell lung cancer (NSCLC) expressing the ALK-EML4 (echinoderm microtubule-associated protein-like 4) fusion protein that causes proliferation of NSCLC

    Categories: Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index, P-glycoprotein inhibitorsSynonyms: 9-ethyl-6,6-dimethyl-8-[4-(morpholin-4-yl)piperidin-1-yl]-11-oxo-6,11-dihydro-5H-benzo[b]carbazole-3-carbonitrile
  2. Drug

    Lepirudin

    go.drugbank.com/drugs/DB00001
    ApprovedWithdrawn

    [L41539] Lepirudin is produced in yeast cells and is identical to natural hirudin except for the absence of sulfate on the tyrosine residue at position 63 and the substitution of leucine for isoleucine … [A246609] Lepirudin is used as an anticoagulant in patients with heparin-induced thrombocytopenia (HIT), an immune reaction associated with a high risk of thromboembolic complications.

    Synonyms: R-hirudin, Hirudin variant-1
  3. Pathway

    Autophagy

    smpdb.ca/view/SMP0578913
    Signaling

    the fasted state), calcium/calmodulin‑dependent protein kinase kinase 2 (CAMKK2) directly phosphorylates and activates AMPK, which in turn phosphorylates ULK1 to trigger phagophore formation in an mTOR‑independent … An increased AMP:ATP ratio activates AMPK and concurrently inhibits mTORC1, resulting in dephosphorylation and activation of ULK1 kinase activity to nucleate the phagophore.

    Drugs: Adenosine phosphate · Calcium
    Enzymes: Activating molecule in BECN1-regulated autophagy protein 1
  4. Drug

    Fenfluramine

    go.drugbank.com/drugs/DB00574
    ApprovedIllicitInvestigationalWithdrawn

    [A214688, A214691, A214700] Fenfluramine was granted initial FDA approval in 1973 prior to its withdrawal; it was granted a new FDA approval on June 25, 2020, for treatment of patients with Dravet syndrome … from the market in 1997.

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Cytochrome P-450 SubstratesSynonyms: DL-Fenfluramine, 1-(m-trifluoromethyl-phenyl)-2-ethylaminopropane
  5. Drug

    Senna leaf

    go.drugbank.com/drugs/DB15889
    ApprovedInvestigational

    Mixtures: Cholasyn II, Senna SSynonyms: Cassia senna l.
  6. Drug

    Lisdexamfetamine

    go.drugbank.com/drugs/DB01255
    ApprovedInvestigational

    Lisdexamfetamine is a prodrug of [dextroamphetamine], a central nervous system stimulant known as d-amphetamine,[A40246] covalently attached to the naturally occurring amino acid L-lysine. … [A2230] Lisdexamfetamine is the first chemically formulated prodrug stimulant [A40246] and was first approved by the FDA in April 2008.[A2230] It was also approved by Health Canada in February 2009.

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeProducts: SAMEXID® 50MG, SAMEXID® 30 MG
  7. Drug

    Esmirtazapine

    go.drugbank.com/drugs/DB06678
    Investigational

    Merck has terminated its internal clinical development program for esmirtazapine as of March 2010. … Esmirtazapine is the (S)-(+)-enantiomer of mirtazapine and possesses similar overall pharmacology.

    Categories: Cytochrome P-450 Substrates, Heterocyclic Compounds, 3-RingSynonyms: (S)-1,2,3,4,10,14b-hexahydro-2-methylpyrazino(2,1-a)pyrido(2,3-c)(2)benzazepine
  8. Drug

    Fluorometholone

    go.drugbank.com/drugs/DB00324
    ApprovedInvestigational

    A glucocorticoid employed, usually as eye drops, in the treatment of allergic and inflammatory conditions of the eye. It has also been used topically in the treatment of various skin disorders.

    Mixtures: FLUFORTE-N-LIQUIFILM, FLU-SURE T® SUSPENSIÓN OFTÁLMICACategories: Corticosteroids, Moderately Potent (Group II), Agents for Treatment of Hemorrhoids and Anal Fissures for Topical Use
  9. Drug

    Bimekizumab

    go.drugbank.com/drugs/DB12917
    ApprovedInvestigational

    Bimekizumab is a humanized monoclonal antibody directed towards IL-17, which was approved for use in the EU on August 20, 2021, for the treatment of plaque psoriasis. … [A244455] It has demonstrated superior efficacy as compared to another IL-17 inhibitor, [secukinumab], as well as [ustekinumab] (an IL-12/23 inhibitor) and [adalimumab] (a TNF inhibitor) in the treatment

  10. Drug

    Clascoterone

    go.drugbank.com/drugs/DB12499
    ApprovedInvestigational

    [A218846] In August 2020, FDA approved clascoterone for the first-in-class topical treatment of acne (acne vulgaris) in male and female patients 12 years and older. … Clascoterone (cortexolone 17α-propionate, CB-03-01) is a novel antagonist of androgen receptors. It binds to androgen receptors with high affinity.

    Categories: Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP2B6 Inhibitors